LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Registration Number
- NCT00805194
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The present trial will be performed to evaluate whether BIBF 1120 in combination with standard therapy of docetaxel in patients with stage IIIB/IV or recurrent NSCLC is more effective as compared to placebo in combination with standard therapy of docetaxel. A secondary aim is to obtain safety information as well as information on quality of life of patients treated with BIBF 1120 in combination to standard therapy with docetaxel. In addition, blood will be collected for pharmacokinetic analysis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1314
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo plus docetaxel placebo plus docetaxel Placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel BIBF 1120 plus docetaxel BIBF 1120 plus docetaxel BIBF 1120 2 times daily along with standard therapy of docetaxel
- Primary Outcome Measures
Name Time Method Progression Free Survival (PFS) as Assessed by Central Independent Review From randomisation until cut-off date 2 November 2010 (when 713 PFS events were observed) Progression Free Survival (PFS) as assessed by central independent review according to the modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) . Progression free survival (PFS) is defined as the duration of time from date of randomisation to date of progression or death (whatever occurs earlier).
Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.
- Secondary Outcome Measures
Name Time Method Duration of Confirmed Objective Tumour Response From randomisation until cut-off date 15 February 2013 The duration of objective response is the time from first documented (CR) or (PR) to the time of progression or death and evaluated according to the modified RECIST criteria version 1.0.
As per RECIST v1.0, Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions.
Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.
This endpoint was analysed based on the central independent reviewer as well as the investigator.Time to Confirmed Objective Tumour Response From randomisation until cut-off date 15 February 2013 Time to confirmed objective response is defined as time from randomisation to the date of first documented (CR) or (PR) and evaluated according to the modified RECIST criteria version 1.0.
Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.
This endpoint was analysed based on the central independent reviewer as well as the investigator.Disease Control From randomisation until cut-off date 15 February 2013 Disease control was defined as a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) and evaluated according to the modified RECIST criteria version 1.0.
As per RECIST v1.0 for target lesions : Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.
This endpoint was analysed based on the central independent reviewer as well as the investigator.Quality of Life (QoL) From randomisation until cut-off date 15 February 2013 Quality of life (QoL) was measured by standardised questionnaires (Health Status Self-Assessment Questionnaire (EQ-5D), EORTC Quality of life questionnaire - Core 30 (EORTC QLQ-C30), Quality of life questionnaire - lung cancer module (EORTC QLQ-LC13). The EORTC QLQ-C30 comprises of 30 questions, using both multi-item scales and single-item measures. EORTC LC-13 comprises of 13 questions incorporating 1 multi-item scale and a series of single items.
The following were the main points of interest:
Time to deterioration of cough (EORTC QLQ-LC13 question 1), Time to deterioration of dyspnoea (QLQ-LC13, composite of questions 3 to 5), Time to deterioration of pain (QLQ- C30, composite of questions 9 and 19).
Time to deterioration of cough, dyspnoea and pain was defined as the time to a 10-point increase from the baseline score.
Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curveDuration of Disease Control From randomisation until cut-off date 15 February 2013 The duration of disease control was defined as the time from randomisation to the date of disease progression or death (which ever occurs first) for patients with disease control.
Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.
This endpoint was analysed based on the central independent reviewer as well as the investigator.Clinical Improvement From randomisation until cut-off date 15 February 2013 Clinical improvement was defined as the time from randomisation to deterioration in body weight and/or Eastern Cooperative Oncology group performance score (ECOG PS) whichever occurred first.
Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.Dose Normalised Predose Plasma Concentration at Steady State (Cpre,ss,Norm) of Nintedanib and of Its Metabolites BIBF 1202 and BIBF 1202 Glucuronide Before the administration of nintedanib or placebo and between a window of 30 mins to an hour after administration of trial drug during Course 2 and between 1 and 3 hours after administration of trial drug during Course 3 Geometric mean of dose normalised predose plasma concentration (Cpre,ss,norm) of nintedanib and of its metabolites BIBF 1202 and BIBF 1202 glucuronide evaluated at steady state based on course 2 and 3. If only one value was available and valid, then this value was used for calculation of Cpre,ss,norm.
Overall Survival (Key Secondary Endpoint) From randomisation until cut-off date 15 February 2013 (approximately 48 months or 1151 deaths among all patients ) Overall Survival (OS) defined as the duration from randomisation to death (irrespective of the reason of death). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.
A fixed-sequence-testing was implemented for key secondary endpoint if both the primary and the follow-up analysis showed a treatment benefit (P\<0.05) of nintedanib over placebo. In this case, the OS would be tested using hierarchical testing of statistical hypotheses in (1) patients with adenocarcinoma and \<9 months since start of first-line therapy, (2) patients with adenocarcinoma, and (3) all patients. Each hypothesis could be only tested at the pre-specified alpha level if the previous null hypothesis in the testing sequence had been.Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Central Independent Review From randomisation until cut-off date 15 February 2013 Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by central independent review according to the modified RECIST (version 1.0) criteria.
Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Investigator From randomisation until cut-off date 15 February 2013 Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by investigator according to the modified RECIST (version 1.0) criteria.
Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.Objective Tumour Response From randomisation until cut-off date 15 February 2013 Confirmed objective response is defined as confirmed Complete Response (CR) and Partial Response (PR) and evaluated according to the modified RECIST criteria version 1.0.
As per RECIST v1.0, Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions.
This endpoint was analysed based on the central independent reviewer as well as the investigator.Change From Baseline in Tumour Size From randomisation until cut-off date 15 February 2013 Percentage change from baseline in tumour size is defined as decrease in the sum of the longest diameter of the target lesion.
Presented means are in fact adjusted best means percentage changes generated from ANOVA model adjusted for baseline ECOG PS (0 vs. 1), tumour histology (squamous vs non-squamous), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no)
This endpoint was analysed based on the central independent reviewer as well as the investigator.Incidence and Intensity of Adverse Events From the first drug administration until 28 days after the last drug administration, up to 42 months Incidence and intensity of adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The worst CTCAE grade per patient is reported and MedDRA version 15.1 used.
Serious signs and symptoms of progressive disease were reported as an adverse event in analysis of this endpoint.
Trial Locations
- Locations (208)
Brest Regional Clinical
🇧🇾Brest Region, Belarus
KH St. Vinzenz, Zams, Int. Abtlg.
🇦🇹Kufstein, Austria
Specialized Hospital for Active Treatment in Oncolcogy
🇧🇬Sofia, Bulgaria
Interdistrict Oncology Dispensary, Ruse
🇧🇬Ruse, Bulgaria
Jiangsu Cancer Hospital
🇨🇳Nanjing, China
Jilin Province Cancer Hospital
🇨🇳Changchun, China
Southwest Hospital
🇨🇳Chongqing, China
Multiprofile Hospital for Active Treatment
🇧🇬Gabrovo, Bulgaria
District Oncology Dispensary Shumen
🇧🇬Shumen, Bulgaria
Centre Hospitalier Universitaire de Liège
🇧🇪Liège, Belgium
First Hospital of Jilin University
🇨🇳Changchun, China
District Oncology Dispensary Plovdiv
🇧🇬Plovdiv, Bulgaria
West China Hospital
🇨🇳Chengdu, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, China
Shanghai Pulmonary Hospital
🇨🇳Shanghai, China
Hospital Arnau de Vilanova
🇪🇸Valencia, Spain
University Hospital Brno
🇨🇿Brno, Czechia
Faculty Hospital Trnava
🇸🇰Trnava, Slovakia
Parklands Hospital
🇿🇦Durban, South Africa
FSBI "N.N. Petrov National Medical Research Center of Oncology" of MoH of RF
🇷🇺St. Petersburg, Russian Federation
GVI oncology Medi Clinic
🇿🇦Cape Town, South Africa
GUZ Sverdlovsky Regional Oncology Dispensary
🇷🇺Yekaterinburg, Russian Federation
HOP Nord Laënnec
🇫🇷Saint Herblain cedex, France
Hospital Jerez de la Frontera
🇪🇸Jerez De La Frontera-Cádiz, Spain
Langenhoven Drive Oncology Centre
🇿🇦Port Elizabeth, South Africa
Amtel Hospital first Clinical LLC
🇬🇪Tbilisi, Georgia
Fundación Instituto Valenciano de Oncologia
🇪🇸Valencia, Spain
Hospital Universitario de Elche
🇪🇸Elche, Spain
Kantonsspital Aarau
🇨🇭Aarau, Switzerland
Wilgers oncology
🇿🇦Pretoria, South Africa
Kantonsspital Baden AG
🇨🇭Baden, Switzerland
Chernigiv Regional Oncology Centre
🇺🇦Chernigiv, Ukraine
Ternopil regional communal clinical oncology centre
🇺🇦Ternopil, Ukraine
Hospital Clínic de Barcelona
🇪🇸Barcelona, Spain
SBIH of Stavropol territory "Pyatigorsk Oncol. Dispensary"
🇷🇺Pyatigorsk, Russian Federation
Pretoria Academic Hospital
🇿🇦Pretoria, South Africa
Hospital Quirónsalud Madrid
🇪🇸Pozuelo de Alarcon, Spain
Wythenshawe Hospital
🇬🇧Manchester, United Kingdom
Chmelnytskyi Oblasnnyi Oncologichnyi Tsentr
🇺🇦Chmelnytskyi, Ukraine
Kharkiv Medical Acadamy of Postgraduate education
🇺🇦Kharkiv, Ukraine
Poole Hospital
🇬🇧Poole, United Kingdom
Bukovynsk State Medical University
🇺🇦Chernivtsi, Ukraine
Royal Bournemouth and Christchurch Hospital
🇬🇧Bournemouth, United Kingdom
Independent Public Hospital in Suwalki
🇵🇱Suwalki, Poland
Uzhgorod National University, Oncology Centre
🇺🇦Uzhgorod, Ukraine
Papageorgiou Hospital, 1st Cardiological Cl., Thessaloniki
🇬🇷Thessaloniki, Greece
Liège - HOSP CHR de la Citadelle
🇧🇪Liège, Belgium
Herlev Hospital
🇩🇰Herlev, Denmark
First Affiliated Hospital of Dalian Medical University
🇨🇳Dalian, China
Fujian Provincial Tumor Hospital
🇨🇳Fujian, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, China
Zhongshan Hospital Fudan University
🇨🇳Xuhui Area, Shanghai, China
Fond. Poliambulanza Istituto
🇮🇹Brescia, Italy
AKH d. Stadt Linz, Pulmologie
🇦🇹Linz, Austria
Mogilov Regional Oncological Dispensary
🇧🇾Mogilov, Belarus
Public Health Inst. Minsk City Clinical Oncology Dispensary
🇧🇾Minsk, Belarus
LKH-Univ. Hospital Graz
🇦🇹Graz, Austria
Bobruisk Inter-distict
🇧🇾Bobruisk, Belarus
Vitebsk Regional Clinical Oncology Dispensary
🇧🇾Vitebsk, Belarus
Vedanta Institute of Medical Sciences
🇮🇳Ahmedabad, India
Indraprastha Apollo Hospitals
🇮🇳New Delhi, India
Regional Cancer Center
🇮🇳Trivandrum, Kerala, India
King George Hospital
🇮🇳Visakhapatnam, India
Gomel Regional Clinical
🇧🇾Gomel, Belarus
Scientific Research Minsk
🇧🇾Minsk Region, Belarus
Sir Gangaram Hospital
🇮🇳New Delhi, India
Rajiv Gandhi Cancer Institute and Research Centre
🇮🇳New Delhi, India
City Cancer Centre, Cancer Hospital & Research
🇮🇳Vijayawada, India
Hospital of Lithuanian Univ.of HealthSciences Kauno Klinikos
🇱🇹Kaunas, Lithuania
Jawaharlal Nehru Cancer Hospital & Research Centre
🇮🇳Bhopal, M.P., India
Chemotherapy & Immunotherapy Clinic 'Medulla', Tbilisi
🇬🇪Tbilisi, Georgia
Institute of Oncology 'Prof. Dr. Alexandru Trestioreanu'
🇷🇴Bucuresti, Romania
Birla Cancer Centre
🇮🇳Jaipur, India
Bhagwan Mahaveer Cancer Hospital & Research Center, Jawahar
🇮🇳Jaipur, India
Siauliu ligonine, Siauliai
🇱🇹Siauliai, Lithuania
Spitalul Clinic Judetean de Urgenta Brasov
🇷🇴Brasov, Romania
IPO Lisboa Francisco Gentil, EPE
🇵🇹Lisboa, Portugal
CHLN, EPE - Hospital de Santa Maria
🇵🇹Lisboa, Portugal
Oncomed SRL
🇷🇴Timisoara, Romania
Klinikum Frankfurt Höchst GmbH
🇩🇪Frankfurt/Main, Germany
Universitätsklinikum Freiburg
🇩🇪Freiburg, Germany
Evangelisches Krankenhaus, Witten
🇩🇪Witten, Germany
RBIH "Kursk regional clinical oncology dispensary"
🇷🇺Kursk, Russian Federation
GUZ "Regional Clinical Oncology Dispensary"
🇷🇺Ryazan, Russian Federation
Hospital La Princesa
🇪🇸Madrid, Spain
District Hospital Pribram, Oncology Centrum
🇨🇿Pribram, Czechia
Univ.Multiprofile Hospital "Dr. Georgy Stranski" EAD, Pleven
🇧🇬Pleven, Bulgaria
307 Hospital of PLA
🇨🇳Beijing, China
The Second Affiliated Hospital of Dalian Medical University
🇨🇳Dalian, China
Sir Run Run Shaw Hospital
🇨🇳Hangzhou, China
Sun Yat-Sen University Cancer Center
🇨🇳Guangzhou, China
The Third Affiliated Hospital of Harbin Medical University
🇨🇳Harbin, China
Guangdong General Hospital
🇨🇳Guangzhou, China
Shanghai Chest Hospital
🇨🇳Shanghai, China
Tongji Hospital, Tongji University
🇨🇳Wuhan, China
UHC Zagreb
🇭🇷Zagreb, Croatia
Clinical Hospital Centar Sestre Milosrdnice
🇭🇷Zagreb, Croatia
St. Anna Hospital, 2nd Internal Department
🇨🇿Brno, Czechia
Institut onkologie a rehabilitace Na Plesi s.r.o.
🇨🇿Nova Ves pod Plesi, Czechia
District Hospital Liberec
🇨🇿Liberec, Czechia
Odense Universitetshospital
🇩🇰Odense C, Denmark
HOP Croix Rousse, Pneumo, Lyon
🇫🇷Lyon Cedex 4, France
HOP Lyon Sud
🇫🇷Pierre Bénite cedex, France
CHU de Rouen - Hôpital de Bois Guillaume
🇫🇷ROUEN cedex, France
INS Paoli-Calmettes
🇫🇷Marseille Cedex 9, France
Oncology Institute of the Loire
🇫🇷Saint-Priest en Jarez, France
HOP Civil
🇫🇷Strasbourg cedex, France
Sainte Anne Training hospital for the armies
🇫🇷Toulon Cedex 09, France
National Centre of Oncology
🇬🇪Tbilisi, Georgia
Zentralklinik Bad Berka GmbH
🇩🇪Bad Berka, Germany
Evangelische Lungenklinik Berlin
🇩🇪Berlin-Buch, Germany
Gemeinschaftspraxis Dr. Brudler / Dr. Heinrich, Augsburg
🇩🇪Augsburg, Germany
Helios Klinikum Emil von Behring
🇩🇪Berlin, Germany
Krankenhaus Nordwest, Frankfurt
🇩🇪Frankfurt/Main, Germany
Universitätsklinikum Benjamin Franklin, Berlin
🇩🇪Berlin, Germany
Universitätsklinikum Frankfurt
🇩🇪Frankfurt, Germany
Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH
🇩🇪Großhansdorf, Germany
Krankenhaus Martha-Maria Halle-Dölau gGmbH
🇩🇪Halle/Saale, Germany
Asklepios Fachkliniken München-Gauting
🇩🇪Gauting, Germany
Universitätsklinikum Heidelberg
🇩🇪Heidelberg, Germany
Klinikum Kassel GmbH
🇩🇪Kassel, Germany
POIS Leipzig GbR
🇩🇪Leipzig, Germany
Allgemeines Krankenhaus Harburg, 21075 Hamburg
🇩🇪Hamburg, Germany
Universitätsklinikum Leipzig
🇩🇪Leipzig, Germany
Gemeinschaftspraxis für Hämatologie und Onkologie, Köln
🇩🇪Köln, Germany
Katholisches Klinikum St. Hildegardiskrankenhaus, Mainz
🇩🇪Mainz, Germany
Universitätsklinikum Schleswig-Holstein, Campus Kiel
🇩🇪Lübeck, Germany
Klinik, Löwenstein
🇩🇪Löwenstein, Germany
Pius-Hospital, Oldenburg
🇩🇪Oldenburg, Germany
Universitätsklinik links der Isar, München, Ziemssenstr. 1
🇩🇪München, Germany
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
🇩🇪Mainz, Germany
Klinikum rechts der Isar der Technischen Universität München
🇩🇪München, Germany
Städt. Krankenhaus, München-Bogenhausen
🇩🇪München, Germany
Helios Dr. Horst Schmidt Kliniken Wiesbaden
🇩🇪Wiesbaden, Germany
Universitätsklinikum Tübingen
🇩🇪Tübingen, Germany
General Hospital of Thessaloniki "G. Papanikolaou"
🇬🇷Thessaloniki, Greece
Athens Hospital of Chest Diseasea "SOTIRIA"
🇬🇷Athens, Greece
University Hospital of Heraklion, University Pulmonology Cl
🇬🇷Heraklio, Greece
Iaso General Hospital
🇬🇷Holargos, Athens, Greece
KIDWAI memoraial Institute of oncology
🇮🇳Bangalore, India
Apollo Hospital
🇮🇳Chennai, India
Rajalakshmi Multispeciality Hospital
🇮🇳Bangalore, India
SEAROC cancer center,S.K.soni Hospital
🇮🇳Jaipur, Rajasthan, India
B. P .Poddar Hospital & Medical Research Ltd.
🇮🇳Kolkata, West Bengal, India
Tata Memorial Centre
🇮🇳Mumbai, India
Shatabdi Superspeciality Hospital
🇮🇳Nashik, India
Kasturba Medical College and Hospital
🇮🇳Mangalore, India
Jehangir Hospital Oncology Department
🇮🇳Pune, Maharahtra, India
E. Wolfson Medical Center, Holon 58100
🇮🇱Holon, Israel
Hadassah Medical Center, Ein-Karem
🇮🇱Jerusalem, Israel
Meir Medical Center
🇮🇱Kfar Saba, Israel
The Chaim Sheba Medical Center Tel Hashomer
🇮🇱Tel Hashomer, Israel
Sourasky Medical Center
🇮🇱Tel-Aviv, Israel
Assaf Harofe Medical Center
🇮🇱Zerifin, Israel
ASST Grande Ospedale Metropolitano Niguarda
🇮🇹Milano, Italy
Azienda Sanitaria Ospedale S. Luigi Gonzaga
🇮🇹Orbassano, Italy
Azienda Ospedaliera Careggi
🇮🇹Firenze, Italy
Policlinico S. Orsola Malpighi
🇮🇹Bologna, Italy
Az. Ospedaliere Umberto I di Ancona
🇮🇹Ancona, Italy
Centro di riferimento Oncologico
🇮🇹Aviano, Italy
Ospedale Civile
🇮🇹Ivrea (TO), Italy
Fondazione Salvatore Maugeri
🇮🇹Pavia, Italy
Istituto Scientifico Romagnolo
🇮🇹Meldola, Italy
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
Ospedale S.Maria della Misericordia, AO di Perugia
🇮🇹Perugia, Italy
The Catholic University of Korea, Seoul St.Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Regional Complex Hospital
🇵🇱Elblag, Poland
VHS Medical Center
🇰🇷Seoul, Korea, Republic of
Vilniaus Universiteto
🇱🇹Vilnius, Lithuania
Institute of Tuberculosis & Pulmonology, III. Dept., Olsztyn
🇵🇱Olsztyn, Poland
Regional Specialist Hospital
🇵🇱Slupsk, Poland
Greater PL Cent.Pulmo.&Thor.Surg.Eugenia&Janusz Zeyland
🇵🇱Poznan, Poland
Mazowieckiego Centrum
🇵🇱Otwock, Poland
Specialist Hospital, Szczecin-Zdunowo
🇵🇱Szczecin, Poland
Onco.Cent. - Instit. of Maria Sklodowskiej-Curie
🇵🇱Warszawa, Poland
IPO Porto Francisco Gentil, EPE
🇵🇹Porto, Portugal
Baia Mare Emergency County Hospital
🇷🇴Baia Mare, Romania
Centro Hospitalar São João,EPE
🇵🇹Porto, Portugal
CHS, EPE - Hospital de São Bernardo
🇵🇹Setúbal, Portugal
Centro Hospitalar de Vila Nova de Gaia
🇵🇹Vila Nova de Gaia, Portugal
Institutul Oncologic "Prof. Dr. Ion Chiricuta"
🇷🇴Cluj-Napoca, Romania
Centrul de Oncologie Medicala
🇷🇴Iasi, Romania
County Hospital "Dr. Alex Simionescu"
🇷🇴Hunedoara, Romania
Onesti County Hospital
🇷🇴Onesti, Romania
Emergency County Hospital "Sf.loan cel Nou"
🇷🇴Suceava, Romania
Emergency Clinical County Hospital "Sf Spiridon", Iasi
🇷🇴Iasi, Romania
SBIH of Arkhangelsk reg. "Arkhangelsk Clin. Onc. Dispensary"
🇷🇺Arkhangelsk, Russian Federation
GUZ Irkutsk Regional Oncology Dispensary
🇷🇺Irkutsk, Russian Federation
St.Auton.Heal.Inst."Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan"
🇷🇺Kazan, Russian Federation
GLPU Cheliabinsky
🇷🇺Chelyabinsk, Russian Federation
FSBI "N.N Blokhin Med.Res.Cent.Onc."MoH of RF
🇷🇺Moscow, Russian Federation
GUZ Regional Oncology Dispensary, Magnitogorsk
🇷🇺Magnitogorsk, Russian Federation
GUZ Leningradskaya Regional Clin. Hospital, St. Petersburg
🇷🇺St. Petersburg, Russian Federation
GUZ "Oncological Dispesary #2"
🇷🇺Sochi, Russian Federation
SPb SBIH "City Clinical Oncological Dispensary"
🇷🇺St. Petersburg, Russian Federation
1stPavlov St.Med.Univ.St.-Petersburg Res.Inst.
🇷🇺St. Petersburg, Russian Federation
Medical Oncology Centre of Rosebank
🇿🇦Johannesburg, South Africa
WCR CMJAH Clinical Trial Site
🇿🇦Johannesburg, South Africa
Servicio de Oncologia Radiotherapica
🇪🇸Valencia, Spain
Odesa Regional Oncological Centre
🇺🇦Odesa, Ukraine
Vinnytsia Regional Clinical Oncological Dispensary
🇺🇦Vinnytsia, Ukraine
Broomfield Hospital
🇬🇧Chelmsford, United Kingdom
Bristol Haematology & Onc. Ctr
🇬🇧Bristol, United Kingdom
Pulmonology Center in Bydgoszcz
🇵🇱Bydgoszcz, Poland
City Clinical Hospital #4, Dnipropetrovsk State Medical Academy
🇺🇦Dnipropetrovsk, Ukraine
Kryvorizskyi regional communal clinical oncology centre
🇺🇦Kryvyi Rig, Ukraine
Donetsk Regional Antitumor Centre
🇺🇦Donetsk, Ukraine
the 81th Hospital of PLA
🇨🇳Nanjing, China